🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/12/2000 | 75,75 | 77,63 | 72,81 | 75,81 | +0,83% | 6,35% | 1.262.900 |
| 12/12/2000 | 81,63 | 81,69 | 72,75 | 75,19 | -8,10% | 10,95% | 1.411.200 |
| 11/12/2000 | 78,25 | 84,50 | 78,13 | 81,81 | +4,28% | 8,15% | 1.097.700 |
| 08/12/2000 | 73,00 | 79,00 | 72,38 | 78,45 | +11,88% | 9,08% | 1.776.600 |
| 07/12/2000 | 69,88 | 72,50 | 67,00 | 70,13 | -0,80% | 7,87% | 989.800 |
| 06/12/2000 | 70,13 | 73,50 | 68,00 | 70,69 | +0,89% | 7,84% | 1.096.900 |
| 05/12/2000 | 64,75 | 70,63 | 64,38 | 70,06 | +13,12% | 9,65% | 1.627.200 |
| 04/12/2000 | 64,38 | 64,63 | 58,13 | 61,94 | -5,71% | 10,10% | 733.600 |
| 01/12/2000 | 59,13 | 70,31 | 58,63 | 65,69 | +17,56% | 19,77% | 2.033.900 |
| 30/11/2000 | 57,88 | 61,48 | 55,63 | 55,88 | -8,78% | 10,12% | 1.204.600 |
| 29/11/2000 | 65,50 | 66,25 | 60,25 | 61,25 | -2,20% | 9,16% | 831.100 |
| 28/11/2000 | 71,81 | 72,50 | 62,00 | 62,63 | -14,94% | 14,62% | 1.662.500 |
| 27/11/2000 | 69,09 | 74,63 | 68,63 | 73,63 | +13,38% | 8,68% | 1.656.300 |
| 24/11/2000 | 59,50 | 65,25 | 57,25 | 64,94 | +18,07% | 13,45% | 618.900 |
| 22/11/2000 | 52,69 | 59,19 | 52,63 | 55,00 | -1,12% | 12,46% | 1.656.100 |
| 21/11/2000 | 56,31 | 57,81 | 53,81 | 55,63 | +1,14% | 7,10% | 1.224.000 |
| 20/11/2000 | 61,88 | 62,69 | 51,50 | 55,00 | -12,87% | 18,08% | 1.747.100 |
| 17/11/2000 | 68,38 | 68,50 | 59,00 | 63,13 | -6,83% | 13,89% | 1.744.900 |
| 16/11/2000 | 72,56 | 72,63 | 67,13 | 67,75 | -7,98% | 7,58% | 1.330.100 |
| 15/11/2000 | 74,44 | 77,50 | 72,13 | 73,63 | +0,51% | 7,22% | 1.734.600 |
| 14/11/2000 | 77,95 | 78,00 | 71,00 | 73,25 | +2,90% | 8,98% | 1.991.000 |
| 13/11/2000 | 79,50 | 82,06 | 68,56 | 71,19 | -19,85% | 16,98% | 2.323.700 |
| 10/11/2000 | 86,63 | 90,13 | 86,00 | 88,81 | -2,40% | 4,76% | 679.900 |
| 09/11/2000 | 92,50 | 93,38 | 88,50 | 91,00 | -2,41% | 5,27% | 961.600 |
| 08/11/2000 | 96,88 | 98,88 | 92,00 | 93,25 | -3,73% | 7,10% | 502.600 |
| 07/11/2000 | 91,00 | 98,50 | 89,75 | 96,86 | +5,64% | 9,62% | 1.177.600 |
| 06/11/2000 | 93,88 | 95,25 | 91,00 | 91,69 | -2,33% | 4,53% | 968.000 |
| 03/11/2000 | 97,25 | 98,75 | 93,75 | 93,88 | -3,47% | 5,14% | 1.043.800 |
| 02/11/2000 | 95,50 | 98,50 | 95,38 | 97,25 | +2,57% | 3,27% | 1.414.300 |
| 01/11/2000 | 92,69 | 99,25 | 91,50 | 94,81 | +1,83% | 8,36% | 1.662.200 |